Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Accounts Payable & Accrued Expense : $41.94 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals Accounts Payable & Accrued Expense?

Tarsus Pharmaceuticals's quarterly accounts payable & accrued expense increased from Sep. 2023 ($22.83 Mil) to Dec. 2023 ($36.54 Mil) and increased from Dec. 2023 ($36.54 Mil) to Mar. 2024 ($41.94 Mil).

Tarsus Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2021 ($10.12 Mil) to Dec. 2022 ($14.71 Mil) and increased from Dec. 2022 ($14.71 Mil) to Dec. 2023 ($36.54 Mil).

Tarsus Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Tarsus Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tarsus Pharmaceuticals Accounts Payable & Accrued Expense Chart

Tarsus Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.76

4.80

10.12

14.71

36.54

Tarsus Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															12.55	14.33	22.83	36.54	41.94

Tarsus Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618

Website

https://www.tarsusrx.com

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Executives

Bobak R. Azamian	director, 10 percent owner, officer: President and CEO	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Jose M. Trevejo	officer: Chief Medical Officer	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg	director	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Dianne C. Whitfield	officer: Chief Human Resources Officer	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl	officer: General Counsel	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin	director	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jeffrey S Farrow	officer: See Remarks	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Leonard M. Greenstein	officer: Chief Financial Officer	24562 BELGREEN PLACE, LAKE FOREST CA 92630
Seshadri Neervannan	officer: Chief Operating Officer	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Mark J. Holdbrook	officer: V.P., Clinical Affairs	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann	director, 10 percent owner	202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Rosemary A Crane	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873